A retrospective study evaluating weekly intermittent dosing regimen of vismodegib in patients with advanced basal cell carcinoma.

Trial Profile

A retrospective study evaluating weekly intermittent dosing regimen of vismodegib in patients with advanced basal cell carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2017 New trial record
    • 18 Jan 2017 Results published in the JAMA Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top